|Bid||84.77 x 100|
|Ask||84.78 x 300|
|Day's Range||84.72 - 85.14|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.88|
|Dividend & Yield||2.72 (3.27%)|
|1y Target Est||89.50|
Roche, Celgene and Novartis could change the multiple sclerosis landscape, a sector now dominated by Biogen.
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.